Preview

Онкоурология

Расширенный поиск

Правильно ли мы лечим рак предстательной железы?

https://doi.org/10.17650/1726-9776-2006-2-1-48-56

Полный текст:

Об авторах

В. Б. Матвеев
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


Б. Я. Алексеев
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


М. И. Волкова
ГУ РОНЦ им. Н.Н. Блохина РАМН
Россия


Список литературы

1. Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86—10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate // Int. J. Radiat. Oncol. Biol. Phys. — 2001;50:1243—1252.

2. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85—31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate // Int J. Radiat. Oncol. Biol. Phys. — 2001;49:937—946.

3. Bolla M., Gonzalez D., Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin // N. Engl. J. Med. — 1997;337:295—300.

4. Hanks G.E., Lu J., Machtay M. et al. RTOG Protocol 92—02: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate // Proc. Am. Soc. Clin. Oncol. — 2000;19:1284.

5. Byar D.P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate // Cancer. — 1973:32:1126—1130.

6. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred hormone therapy for prostate cancer: How safe is androgen deprivation? // BJU Int. — 2000;86:220.

7. Schroder F.H., Kurth K.H., Fossa S.D. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study // J. Urol. — 2004; Sep;172(3):923—927.

8. Van Poppel H. Treatment options for locally advanced prostate cancer.//Controversies in the management of bladder cancer and prostate cancer. — Bologna, 21—23 January, 2005. — P. 47.

9. Gleave M.E., Goldenberg S.L., Chin J.L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects // J. Urol. — 2001;166: 500—507.

10. Schulman C.C., Debruyne F.M., Forster G. et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2—3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer // Eur. Urol. — 2000;38:706—713.

11. Soloway M.S., Pareek K., Sharifi R. et al.. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. Lupron Depot Neoadjuvant Prostate Cancer Study Group // J. Urol. — 2002;167:112—116.

12. Zincke H, Lau W, Bergstralh E, et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer// J. Urol. — 2001;166:2208—2215.

13. Wirth M., Frohmuller H., Marz F. et al. Randomized multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery: Interim analysis of treatment effect and prognostic factors [abstract] // Br. J. Urol. — 1997;80:263.

14. See W., McLeod D. Iversen P.et al. The bicalutamide Early Prostate Cancer Program: Findings of the North American Trial at median 5.7 years` follow-up // J. Urol. — 2005. — V. 173, № 4. — Abstr. 674.

15. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer //Cancer J. Clin. — 2002. — V. 52 (3). — P. 154—179.

16. Benson RC. Total androgen blockade: the United States experience // Eur. Urol. — 1993;24(2):72—76.

17. Denis L.J., Carnelro de Moura J.L. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853) EORTC GU Group and EORTC Data Center // Urology. — 1993; Aug;42(2):119—129; discussion 129—130.

18. Eisenberger M.A., Crawford E.D., Wolf M Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036 // Semin. Oncol. — 1994; Oct;21(5):613—619.

19. Klotz L. // BJU Int. — 2001; 87: 806—813.

20. Moinpour C.M., Savage M.J., Troxel A. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial // J. Natl. Cancer Inst. — 1998; Oct 21;90(20):1537—1544.

21. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials // Lancet. — 2000;355:1491—1498.

22. Zalcberg J.R., Raghaven D., Marshall V., Thompson P.J. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate-an Australian multicentre trial // Br. J. Urol. — 1996; Jun;77(6):865—869.

23. Seidenfeld J., Samson D.J., Hasselblad V. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis //Ann Intern. Med. — 2000. — V. 4, № 132 (7). — P. 566—577.

24. Kasamon K.M., Dawson N. Update on hormone-refractory prostate cancer // Current Opinion in Urology. — 2004;14:185—193.

25. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer //N. Engl. J. Med. — 2004. — V. 7, № 351 (15). — P. 1513—1520.

26. Tannock I.F., de Wit R., Berry W.R. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer // N. Engl. J. Med. — 2004. — V. 7, № 351(15). — P. 1502—1512.

27. Oosterhof G.O., Roberts J.T., de Reijke T.M. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group // Eur. Urol. — 2003; Nov;44(5):519—526.

28. Coleman R.E. Skeletal complications of malignancy //Cancer. — 1997. — V. 80. — P. 1588—1594.


Для цитирования:


Матвеев В.Б., Алексеев Б.Я., Волкова М.И. Правильно ли мы лечим рак предстательной железы? Онкоурология. 2006;2(1):48-56. https://doi.org/10.17650/1726-9776-2006-2-1-48-56

For citation:


Matveev V.B., Alekseev B.Y., Volkova M.I. Do We Treat Prostatic Cancer Correctly? Cancer Urology. 2006;2(1):48-56. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-1-48-56

Просмотров: 18


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X